Heart failure & cardiomyopathies
Simultaneous Vaccination Against Influenza and Respiratory Syncytial Virus in High-Risk Heart Failure Patients
Primary resultResult — go to the resultHazard ratio 0.66 95% CI 0.48–0.92Authors' conclusion
In the population of high-risk HF, simultaneous vaccination against influenza and RSV reduced the incidence of the primary outcome. The effect was driven by a significant reduction in infections.
Study context
- Population
- Patients with high-risk heart failure (HF)
- Participants
- 220 patients
- Comparison
- Simultaneous influenza and respiratory syncytial virus (RSV) vaccination vs standard of care
- Primary endpoint
- Composite of:
- All-cause death
- HF hospitalization
- Clinical signs/symptoms of infection
- Follow-up
- 6 months
Methodological detailssingle-centre, open-label
- Single-centre
- Open-label
Primary result
As reported in the abstract
Hazard ratio
0.66
95% CI 0.48–0.92
P = 0.01
By group
Vaccinationvs SOC
HR 0.66 (95% CI 0.48–0.92); P = 0.01
Secondary outcomes
| Outcome | Vaccination | SOC | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause death · 6 months | 3% | 5% | 0.50 (0.12 1.99) | P = 0.32 | |
| HF hospitalization · 6 months | 18% | 16% | 0.86 (0.45–1.62) | P = 0.64 | |
| Infection · 6 months | 53% | 68% | 0.68 (0.48–0.96) | P = 0.03 | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Simultaneous Vaccination Against Influenza and Respiratory Syncytial Virus in High-Risk Heart Failure Patients. ESC Heart Fail. Published 25 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →